Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo
01 Pubblicazione su rivista
Ferrari Silvia Martina, Bocci Guido, Di Desidero Teresa, Ruffilli Ilaria, Elia Giusy, Ragusa Francesca, Fioravanti Anna, Orlandi Paola, Paparo Sabrina Rosaria, Patrizio Armando, Piaggi Simona, La Motta Concettina, Ulisse Salvatore, Baldini Enke, Materazzi Gabriele, Miccoli Paolo, Antonelli Alessandro, Fallahi Poupak
DOI: 10.3892/or.2018.6305
ISSN: 1021-335X
The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), ERK and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C [undifferentiated thyroid cancer (TC)] and in an ATC-cell line (AF), was investigated in the present study. Vandetanib (1 and 100 nM; 1, 10, 25 and 50 μM) was tested by WST-1, apoptosis, migration and invasion assays: in primary ATC cells, in the 8305C continuous cell line, and in AF cells; and in 8305C cells in CD nu/nu mice. Vandetanib significantly reduced ATC cell proliferation (P